A Phase Ib Study of Linperlisib in the Treatment of Patients with Relapsed and/or Refractory Peripheral T-cell Lymphoma
With the very promising clinical activity against r/r PTCL, the results of this study support the further investigation of linperlisib for the treatment of r/r PTCL.
Authors
- Jie Jin (ORCID: https://orcid.org/0000-0002-8166-9915)
- Zusheng Xu (ORCID: https://orcid.org/0000-0002-7266-6202)
- Zhiming Li (ORCID: https://orcid.org/0000-0001-9730-9917)
- Lugui Qiu (ORCID: https://orcid.org/0000-0002-8752-0644)
- Hong Cen (ORCID: https://orcid.org/0000-0003-2232-9213)
- Haiyan Yang (ORCID: https://orcid.org/0000-0002-1371-3734)
- Keshu Zhou (ORCID: https://orcid.org/0000-0001-5467-1377)
- Hanying Bao (ORCID: https://orcid.org/0000-0002-0846-2774)
- Fei Li (ORCID: https://orcid.org/0000-0002-7765-5975)
- Xiaohong Xu (ORCID: https://orcid.org/0009-0000-9736-0712)
- Tao Wu (ORCID: https://orcid.org/0009-0006-0413-0306)
- Zhen Wang (ORCID: https://orcid.org/0009-0009-9119-7382)
- Wenyang Huang
Institutions
- Nanchang University (CN)
- Sun Yat-sen University (CN)
- Nantong University (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Guizhou Cancer Hospital (CN)
- Cancer Hospital of Chinese Academy of Medical Sciences (CN)
- Henan Cancer Hospital (CN)
- Sun Yat-sen University Cancer Center (CN)
- Institute of Hematology & Blood Diseases Hospital (CN)
- Tumor Hospital of Guangxi Medical University (CN)
- First Affiliated Hospital of Nanchang University (CN)
- University of Chinese Academy of Sciences (CN)
- First Affiliated Hospital Zhejiang University (CN)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2024-09-19
- DOI
- https://doi.org/10.1158/1078-0432.ccr-24-1194
- Citations
- 12
- Primary Topic
- Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 5.10